The GLP-1 beauty market is attracting some of the industry’s largest names, according to a wire report published on 21 October 2026. L’Oréal, Natura and Galderma are described as testing or developing products for the facial volume loss and sagging skin that some people notice after rapid weight loss on GLP-1 drugs. This industry report looks at what each company said, which forecasts are being quoted, what evidence exists and what the announcements leave out. The article describes testing and development, not completed launches, and it is not investment advice.
GLP-1 beauty market: key takeaways
- Three groups are involved: Galderma (about 20% owned by L’Oréal, per the report), L’Oréal itself and Brazil’s Natura.
- Only Galderma has named products, Sculptra and Restylane, and the report says they are not approved specifically for GLP-1 users.
- L’Oréal and Natura described testing; neither named a product, launch date or investment.
- Quoted forecasts include Pfizer’s $150 billion obesity-drug market by 2030 and BCG’s rise in clinical treatment revenue from about $700 million to $2 billion in five years.
- The published company evidence is an open-label study with no control group.
Who said what in the GLP-1 beauty market
The wire report of 21 October 2026 quotes Anne-Cecile Chevrier, Galderma’s global head of injectable aesthetics, saying that sagginess and loss of firmness are concerns. It says Galderma works with tens of thousands of plastic surgeons and aestheticians who market its products to patients on weight-loss drugs. L’Oréal’s chief innovation and prospective officer, Delphine Viguier-Hovasse, said the company is testing products on GLP-1 users in separate studies. Natura’s chief innovation and R&D officer, Manuel Krauss, said it is testing existing products and developing a new generation of treatments, and that the future of beauty cannot be defined by creams alone.
Ownership and positioning in the GLP-1 beauty market
This section is our analysis. The report says L’Oréal owns about 20% of Galderma, which means the two are linked commercially, though they appear to be working on separate approaches: Galderma through clinician-administered injectables and L’Oréal through products tested in its own studies. Natura’s mention of supplements and ingestibles suggests a wider definition of the category than topical skin care. None of the three has disclosed revenue from products aimed at people on GLP-1 drugs.
The numbers shaping the GLP-1 beauty market
The report cites Pfizer’s estimate that obesity drugs could reach $150 billion in annual sales by 2030 and BCG’s 2025 estimate that clinical treatment revenue could grow from about $700 million to $2 billion in five years, an increase of about $1.3 billion by our subtraction. A 2024 Medical Insight report found that 53% of U.S. aesthetics clinics expect new patients from prescription weight-loss drugs and 43% expect more demand for treatments for drug-induced facial changes. KFF analysts say GLP-1 drugs are used most widely by adults aged 50 to 64. All of these are estimates or surveys, not measured sales of products for this use.
The evidence behind the GLP-1 beauty market
In its Galderma’s release on its nine-month study, Galderma reported nine-month results from a Phase IV, open-label study at two U.S. sites of Sculptra with Restylane in patients with facial volume loss after GLP-1 treatment. It said 85.7% reported a less gaunt or sunken face and that no treatment-related adverse events were reported. The study had no control group, did not state its participant numbers, and is cited as data on file. A consultancy brief argues that the opportunity is large and the window to act is short, but it comes from a firm that sells advisory services, and we treat its projections as opinion.
Why clinics lead the GLP-1 beauty market for now
This section is our analysis. The report says Galderma works with tens of thousands of plastic surgeons and aestheticians, and that experts see injectables as reaching the deeper layers where volume is lost, while creams act on the surface. That makes clinics and practitioners the main route to patients today, and it helps explain why the clinical treatment forecast quoted by BCG is far smaller in dollar terms than the obesity drug forecast. Consumer products, if they arrive, would reach a different and larger audience but would face the evidence limits that experts describe.
What a wider GLP-1 beauty market could look like
Natura’s remark about supplements and ingestibles points to a category that could span skin care, nutrition and clinical aesthetics. We have seen no data on whether such products work for weight-loss skin changes, and the dermatologists quoted in the report stress that the causes are several, including age, menopause and nutrition. A product aimed at only one cause may have limited effect, which is a commercial risk as well as a scientific one.
Regulation and claims in the GLP-1 beauty market
This section is general background. Products sold as cosmetics and products regulated as medical devices or medicines face different rules in different countries, and the claims a company can make differ accordingly. The report says Sculptra and Restylane are not approved specifically for GLP-1 users, so marketing to such patients depends on how existing approvals and local rules apply. We do not assess any individual company’s compliance, and we found no regulatory filing aimed at this use.
What is not disclosed
- Named L’Oréal and Natura products, launch dates and investment.
- Revenue from patients on GLP-1 drugs at any of the three companies.
- Participant numbers and statistics for Galderma’s study.
- Independent, peer-reviewed evidence for products aimed at this group.
Risks and caveats on the GLP-1 beauty market
- Forecasts differ by source, and some are produced by firms with a commercial interest.
- Testing and development do not guarantee that a product will reach the market.
- Company-reported results are not independent evidence.
- This is news reporting, not investment or medical advice.
In our assessment, the GLP-1 beauty market is real as a source of customer interest, but for now it is mostly a story of testing and positioning, and the companies’ own disclosures give investors and readers little to measure commercial impact. See also CDC Measles Outbreak Response: Critical Epi-Aid Boost. More in our industry insights coverage.
What to watch next on the GLP-1 beauty market
- Named product launches and claims from L’Oréal and Natura.
- Peer-reviewed publication of the Galderma data.
- Any regulatory clarity on marketing to people taking GLP-1 drugs.
Frequently asked questions
Which companies are targeting GLP-1 skin changes?
The wire report names L’Oréal, Natura and Galderma, with Galderma the only one naming products.
Have L’Oréal and Natura launched products?
Not according to the report, which describes testing and development.
How big is the opportunity?
Quoted forecasts include BCG’s estimate of clinical treatment revenue rising from about $700 million to $2 billion over five years, but these are estimates.
How we reported this: we relied on a wire report of 21 October 2026, Galderma’s release and a consultancy brief, and we have flagged company and advisory claims. Our analysis is labelled. Last updated: 21 October 2026. This article is news reporting and not investment or medical advice.
